Make a graph out of this:

Table 3 summarizes the estimated out-of-pocket spending for a 30-day supply of the most common formulation (20 mg) of brand-name, authorized generic, and other generic atorvastatins during the 3 study segments. During the market exclusivity segment, the median monthly out-of-pocket spending was $17.50 (interquartile range [IQR], $10.02-$49.98). During limited generic competition, out-of-pocket spending for brand-name atorvastatin (median, $16.98; IQR, $8.76-$48.66) was similar to spending for the authorized generic (median, $19.98; IQR, $7.50-$54.90) and Ranbaxy's generic (median, $17.70; IQR, $4.98-$51.48) atorvastatin. During full generic competition, out-of-pocket spending for brand-name atorvastatin (median, $30.00; IQR, $15.00-$91.38) was substantially higher than spending for the authorized generic (median, $5.52; IQR, $3.48-$19.98) or the other generic (median, $5.10; IQR, $3.36-$19.98) atorvastatins.